Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Citius Pharmaceuticals Inc (CTXR) vs iShares Self-Driving EV and Tech (IDRV) Price & Performance

Citius Pharmaceuticals IncTrade
iShares Self-Driving EV and TechTrade

Price performance (Past 24H)

Key statistics

Citius Pharmaceuticals Inc vs iShares Self-Driving EV and Tech — how do they compare? Citius Pharmaceuticals Inc trades at $0.77 (market cap $20.01M), while iShares Self-Driving EV and Tech trades at $37.18. Which is the better fit depends on your goals.

CTXRIDRV
Market Cap
$20.01M
Sector
HealthSector/Thematic
52-Week High
$1.82$45.48
52-Week Low
$0.48$34.49
Enterprise Value
$16.23M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Citius Pharmaceuticals Inc

CTXR trades at $0.7554, up 11.58% today, with a bullish technical signal from moving averages. The company reported a net loss of $37.43M for 2025, with a negative net income margin of -823.34%, but shows revenue growth from its LYMPHIR launch. Recent news highlights commercial expansion and positive clinical data presentations at ASCO 2026.

The outlook is speculative; analyst consensus is strongly bullish (83.3% Buy), but high cash burn and consistent earnings misses pose significant risks. Investment potential hinges on successful commercialization of LYMPHIR to achieve profitability.

iShares Self-Driving EV and Tech

IDRV trades at $37.18, down 0.51% today, with a bullish technical signal from moving averages and key indicators like the ADX suggesting a strong trend. Support levels are firm near $35–$37, while resistance sits at $38–$39. Recent news highlights rising global EV sales, with growth in Europe and China, though U.S. adoption lags. The company has a dividend scheduled for June 2026.

The outlook for IDRV is cautiously optimistic, driven by sector tailwinds from EV adoption and regulatory support. Key risks include competitive pressures from Chinese automakers and sensitivity to fuel price volatility. Analyst sentiment is mixed, with technical strength offset by fundamental data gaps. Investors should monitor upcoming earnings for margin trends and guidance updates.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Citius Pharmaceuticals Inc

Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.

Read more on CTXR

About iShares Self-Driving EV and Tech

IDRV invests in global companies at the forefront of self-driving and electric vehicle innovation. It provides exposure to the full EV value chain, including battery technology and autonomous systems, with top holdings like Albemarle, Rivian, and Tesla.

Read more on IDRV